Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorDo Hyun Park
About this trial
Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable.
Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.
Eligibility criteria
Qualifiers
Be at least 19 years old.
Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
A biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC).
Suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.
Disqualifiers
Innate or post-surgical anatomy that precludes direct sampling of duodenal fluid.
Hemodynamically unstable and unable to have an endoscopy performed.
A large amount of ascites fluid that is not controlled and unable to have an endoscopy performed.
A coagulation disorder that cannot be corrected and unable to have an endoscopy performed.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
263 Participants
are grouped into 2 trial groupsSponsors and collaborators
Do Hyun Park
Lead sponsor
Asan Medical Center
Sponsor institution
The Cleveland Clinic
Collaborator
University of Colorado, Denver
Collaborator
Source ClinicalTrials.gov